EWA
DFTX

EverSource Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

EverSource Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.58K Buy
295
+41
+16% +$696 ﹤0.01% 3219
2025
Q4 		$3.4K Buy
254
+150
+144% +$1.86K ﹤0.01% 3283
2025
Q3 		$1.23K Buy
104
+14
+16% +$131 ﹤0.01% 3697
2025
Q2 		$584 Buy
90
+34
+61% +$224 ﹤0.01% 3865
2025
Q1 		$328 Buy
56
+43
+331% +$308 ﹤0.01% 3582
2024
Q4 		$90 Buy
+13
New +$89 ﹤0.01% 3567

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EverSource Wealth Advisors's DFTX Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Definium Therapeutics (DFTX) stake by 16% in Q1 2026, buying an estimated $696 and bringing the position to 295 shares worth $5.58K. The position accounts for ﹤0.01% of the portfolio, ranked #3219.

EverSource Wealth Advisors first reported a position in DFTX in Q4 2024 and has held it in 6 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • EverSource Wealth Advisors held 295 shares of Definium Therapeutics worth $5.58K as of Q1 2026.
  • EverSource Wealth Advisors bought 41 Definium Therapeutics shares in Q1 2026, an estimated $696.
  • Definium Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3219 holding.
  • EverSource Wealth Advisors first reported a position in Definium Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.